Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for Inmune Bio (INMB) over the last 8 years, with Q2 2025 value amounting to $22.3 million.

  • Inmune Bio's Cash from Financing Activities rose 7135.49% to $22.3 million in Q2 2025 from the same period last year, while for Sep 2025 it was $25.5 million, marking a year-over-year increase of 4316.15%. This contributed to the annual value of $18.2 million for FY2024, which is 53102.96% up from last year.
  • Latest data reveals that Inmune Bio reported Cash from Financing Activities of $22.3 million as of Q2 2025, which was up 7135.49% from $5.3 million recorded in Q1 2025.
  • In the past 5 years, Inmune Bio's Cash from Financing Activities registered a high of $52.9 million during Q3 2021, and its lowest value of -$2.5 million during Q4 2023.
  • Moreover, its 5-year median value for Cash from Financing Activities was $9.8 million (2024), whereas its average is $12.8 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 31636666.67% in 2021, then plummeted by 9743.89% in 2022.
  • Quarter analysis of 5 years shows Inmune Bio's Cash from Financing Activities stood at $52.9 million in 2021, then plummeted by 98.62% to $729000.0 in 2022, then plummeted by 442.94% to -$2.5 million in 2023, then increased by 16.88% to -$2.1 million in 2024, then skyrocketed by 1171.75% to $22.3 million in 2025.
  • Its Cash from Financing Activities stands at $22.3 million for Q2 2025, versus $5.3 million for Q1 2025 and -$2.1 million for Q4 2024.